SCHEMBL4973173

SCHEMBL4973173

Cc1ccc2c(c1)C(c1ccc(Cl)cc1)C(C)(C)O2

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
ABCC9 O60706 6/20 0.38
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HCRTR2 O43614 1/20 0.36
HTR1A P08908 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
HTT P42858 1/20 0.34
GAA P10253 1/20 0.33
PGR P06401 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970458 0.91 HTR1A (0.37) LMNAABCC9SLC6A2HTR1AHTR2C
SCHEMBL3603597 0.85 MAPT (0.33) NPC1MAPTRAB9ASMN1; SMN2SLC6A2
SCHEMBL4969761 0.84 GAA (0.48) ABCC9SLC6A2SLC6A4SLC6A3HTR1A
SCHEMBL4972701 0.82 MAOB (0.40) LMNANPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4970447 0.80 HTR2B (0.38) KCNE1KCNQ1ABCC9HTR2BPGR
SCHEMBL4972270 0.74 KCNE1 (0.38) LMNAKCNE1KCNQ1NPC1MAPT
SCHEMBL15253596 0.72 HTR2C (0.40) LMNAKCNE1KCNQ1SMN1; SMN2SLC6A2
SCHEMBL6279178 0.71 KCNA5 (0.46) LMNAABCC9MAPTSMN1; SMN2GAA
SCHEMBL5868360 0.71 KCNA5 (0.46) LMNAABCC9MAPTSMN1; SMN2GAA
SCHEMBL5868365 0.71 KCNA5 (0.46) LMNAABCC9MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1408036-B1 PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE TAKEDA PHARMACEUTICAL (JP) 2008-08-27 EP disclosed
US-7323577-B2 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-29 US disclosed
US-20060142598-A1 Process for producing benzofuran derivative TAWADA HIROYUKI 2006-06-29 US disclosed
US-7034166-B2 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040210066-A1 Process for producing benzofuran derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-10-21 US disclosed
EP-1408036-A1 PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE Takeda Chemical Industries, Ltd. (JP) 2004-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040210066-A1 Process for producing benzofuran derivative IWS1, HAT1, BRD1 LMNA 2920/4885KCNE1 1572/4885KCNQ1 1756/4885
US-20060142598-A1 Process for producing benzofuran derivative AHR, CBR3, HAT1 LMNA 2863/4885KCNE1 1565/4885KCNQ1 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.